Registered Office: D-4 MIDC, Chikalthana, Aurangabad - 431 006 Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051 CIN:L24230MH1999PLC120720

Tel: 91 22 2653 4444 ; Fax: 91 22 2652 3905; e-mail id : investorrelations@wockhardt.com; Website: www.wockhardt.com

	PARTICULARS	3 MONTHS ENDED	3 MONTHS ENDED	3 MONTHS ENDED	6 MONTHS ENDED	6 MONTHS ENDED	YEAR
		30/09/2020	30/06/2020	30/09/2019	30/09/2020	30/09/2019	31/03/2020
	(Refer notes below)	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
+	Income from Continuing Operations						
	(a) Revenue from Continuing operations	294.96	177.58	304.99	472.54	519.67	890.00
	(b) Other income	14.96	9.74	2.01	24.70	10.62	43.02
-	Total income	309.92	187.32	307.00	497.24	530.29	933.0
_	Expenses from Continuing Operations						
	(a) Cost of materials consumed	106.33	10.68	47.02	117.01	118.23	236.70
- 1	(b) Purchase of stock-in-trade	30.21	50.43	25.74	80.64	41.85	85.2
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(6.81)	14.85	11.64	8.04	6.53	(8.6
	(d) Employee benefits expense	75.59	82.08	82.44	157.67	178.62	325.4
	(e) Finance costs	46.97	58.61	54.29	105.58	110.57	220.1
-	(f) Depreciation and amortisation expense	42.97	46.08	41.14	89.05	85.13	173.3
	(g) Exchange fluctuation loss / (gain), net	19.31	3.30	(11.75)	22.61	(8.38)	(42.8
	(h) Other expenses	82.64	111.79	88.96	194.43	203.32	427.2
	Total expenses	397.21	377.82	339.48	775.03	735.87	1,416.7
	Loss before exceptional items and tax from Continuing Operations (1-2)	(87.29)	(190.50)	(32.48)	(277.79)	(205.58)	(483.6
	Discontinued Operations Profit before exceptional items and tax from Discontinued		13.87	33.96	13.87	73.88	145.3
	Operations						
	Exceptional items- credit/(charge)						
_	a) Continuing Operations- Refer note 3		(142.48)	-	(142.48)	-	•
	b) Discontinued Operations- Refer note 2		1,470.32	-	1,470.32		
-	Total- Exceptional items	(87.29)	1,327.84 (332.98)	(32.48)	1,327.84 (420.27)	(205.58)	(483.6
and a lot	Loss after exceptional items before tax from Continuing Operations (3 ± 5a)	(01.23)	(352,50)	(02.00)	(420.21)	(200.00)	(400.0
	Tax expense of continuing operations : Current tax - credit	(16.39)	(69.89)	(11.87)	(86.28)	(25.82)	(50.8
	Tax pertaining to earlier years		-	-	-	-	3.6
	Deferred tax - (credit)/charge	(13.52)	(44.15)	1.41	(57.67)	(48.84)	(110.8
	Net Loss from Continuing Operations (6 ± 7)	(57.38)	(218.94)	(22.02)	(276.32)	(130.92)	(325.6
	Profit after exceptional items before tax from Discontinued	-	1,484.19	33.96	1,484.19	73.88	145.3
	Operations (4 ± 5b)						
0	Tax expense of discontinued operations:						
	Current tax - charge	- 1	311.49	11.87	311.49	25.82	50.8
	Deferred tax - charge	-	187.37	-	187.37 985.33	48.06	94.5
-	Profit from Discontinued Operations (9 ± 10) Profit / (Loss) for the period (8 ±11)	(57.38)	985.33 766.39	22.09	709.01	(82.86)	(231.1
_	a) Other Comprehensive Income	101.001				1	1
	- Continuing Operations						
	i) Items that will not be reclassified to Profit or Loss -	1.00	2.05	(0.42)	3.05	(0.84)	6.
	(charge)/credit (consisting of re-measurement of net defined						
	benefit (liability)/asset)						
	ii) Income tax relating to items that will not be reclassified to Profit	(0.35)	(0.71)	0.17	(1.06)	0.34	(2.1
	or Loss - (charge)/credit			12.051		10 500	
	iii) Other Comprehensive Income (net of tax)	0.65	1.34	(0.25)	1.99	(0.50)	3.
	from continuing operations						
	 b) Other Comprehensive Income - Discontinued Operations 						
	i) Items that will not be reclassified to Profit or Loss -		(0.04)	(0.05)	(0.04)	(0.09)	(0.1
	(charge)/credit (consisting of re-measurement of net defined		10.04	(0.00)	10.0.0		
	benefit (liability/asset)						
	ii) Income tax relating to items that will not be reclassified to Profit	-	0.01	0.02	0.01	0.03	0.
	or Loss - (charge)/credit			Sold States			
	III) Other Comprehensive Income (net of tax)		(0.03)	(0.03)	(0.03)	(0.06)	(0.1
	from discontinued operations						
	Total Comprehensive Income [12 ± 13a (iii)± 13b(iii)]	(56.73)	767.70	(0.21)	710.97	(83.42)	(227.3
	Paid-up equity share capital (face value of Rs. 5/- each)	55.38	55.37	55.37	55.38	55.37	55. 939.2
5	Other Equity excluding Revaluation Reserves as per balance sheet						939.4
5	Earnings per share for continuing operations (face value of Rs. 5/-						
	each)						
	(*not annualised)	(5.18)*	(19.77)*	(1.99)*	(24.95)*	(11.83)*	(29.4
	(a) Basic (Rs.) (b) Diluted (Rs.)	(5.18)*	(19.77)*	(1.99)*	(24.95)*	(11.83)*	(29.4
	Earnings per share for discontinued operations (face value of Rs.	(0.10)	(is.rij	(1.55)	(a root)	(1.00)	100.
	Earnings per share for discontinued operations (lace value of Rs. 5/- each)			S. States			
	(*not annualised)						
			88.98*	2.00*	88.98*	4.34*	8.5
					00.044	4.32*	
	(a) Basic (Rs.) (b) Diluted (Rs.)	-	88.64*	1.99*	88.61*	4.32	8.3
	(a) Basic (Rs.)	-	88.64*	1.99*	88.61*	4.32	8.3
	(a) Basic (Rs.) (b) Diluted (Rs.)	-	88.64*	1.99*	88.61*	4.32	8.5
	(a) Basic (Rs.) (b) Diluted (Rs.) Earnings per share for continuing and discontinued operations	(5.18)*	88.64* 69.21*	1.99*	64.03*	(7.49)*	(20.

W

Notes To Standalone Results :-

 The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on November 02, 2020. The results have been subjected to limited review by the Statutory Auditors of the Company.

2) The Board of Directors, in their meeting held on June 09, 2020, concluded the Business transfer agreement ("BTA") entered into between the Company and Dr. Reddy's Laboratories Limited ("Purchaser") dated February 12, 2020 read with amendments made time to time for the transfer of the business comprising 62 products and line extensions along with related assets and liabilities, contracts, permits, intellectual properties, employees, marketing, sales and distribution of the same in the Domestic Branded Division in India, Nepal, Bhutan, Sri Lanka and Maldives, and the manufacturing facility at Baddi, Himachal Pradesh, where some of the products which are being transferred were manufactured (together the "Business Undertaking"), to the Purchaser. The consideration for the above said transfer of Business Undertaking for Rs. 1,850 crore was structured as per following :

a) an amount equal to Rs. 1,550 crore (including a deposit of Rs. 67 crore in escrow account towards adjustments for, inter alia, Net working capital, employee liabilities and certain other contractual and statutory liabilities) to be paid on the Closing Date under the BTA. The said amount has been paid by the Purchaser to the Company during the half year ended September 30, 2020 including release of Rs. 63 crore out of the original escrow account of Rs.67 crore and,

b) balance amount equal to Rs. 300 crore out of total consideration of Rs. 1,850 crore has been held back ("Holdback Amount"), by the Purchaser on the Closing Date (i.e., June 09, 2020) for assessment of the impact of the COVID-19 pandemic on the Business Undertaking and shall be released as equal to 2 (two) times the amount by which the revenue exceeds Rs. 480 crore from sales of the products forming part of the said Business Undertaking by the Purchaser during the 12 months post-closing date.

The profit from aforesaid Transfer of Business Undertaking (excluding the Holdback Amount of Rs. 300 crore) amounting to Rs. 1,470.32 crore has been shown as 'Exceptional Items - discontinued operations'.

3) During the half year, the Company reassessed the commercial prospects of the Nutrition Business and decided not to pursue it in near future and therefore, the Nutrition Business assets were classified as assets held for disposal and an impairment loss of Rs. 142.48 crore has been recognised under the head 'Exceptional items - continuing operations'.

4) The Company continues to monitor the impact of COVID-19 on it businesses across the globe, its customers, vendors, employees, productions, supply chain and logistics etc. The Company has exercised due care in significant accounting judgements and estimates in relation to recoverability of receivables, investments and inventories based on the information available to date, both internal and external, while preparing the Company's financial results for the current period.

5) During the quarter ended September 30, 2020, the Company has allotted 21,950 Equity shares of face value of Rs. 5/- each pursuant to exercise of employee stock options.

:2:

The Company is exclusively into Pharmaceutical business Segment.

Previous period / year figures have been recast / re-grouped to conform to the current period's presentation.

FOR WOCKHARDT LIMITED

Thoracción aly

H F KHORAKIWALA CHAIRMAN DIN: 00045608

Mumbai Date : November 02, 2020

7)

Registered Office: D-4 MIDC, Chikalthana, Aurangabad - 431 006 Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051

STATEMENT OF STANDALONE ASSETS AND LIABILITIES

	PARTICULARS	As at Period End 30/09/2020 Unaudited	(Rs. in Crore As at Year End 31/03/2020 Audited
) A	ASSETS		
	Non- Current assets	1 100 00	4 420.0
	a) Property, Plant and Equipment	1,100.02	1,439.0
	b) Right of use assets	552.78 305.89	305.2
	c) Capital work-in-progress		
	d) Intangible assets	112.06	24.3
	e) Intangible assets under development	188.78	
(f) Financial assets		
	(i) Investments in subsidiaries	296.82	296.8
	(ii) Other Investments	0.45	0.4
	(iii) Loans	39.43	38.1
	(iv) Other non- current Financial assets	60.07	56.6
0	g) Non-current tax assets (Net)	96.26	96.2
	h) Deferred lax assets (Net)	116.64	247.4
	i) Other non-current assets	66.68	67.6
1			
	Sub-total- Non-current assets	2,935.88	3,152.9
_	Current assets		
	a) Inventories	339.06	314.9
(b) Financial assets		
	(i) Trade receivables	968.30	939.6
	(ii) Cash and cash equivalents	690.56	108.4
+	(iii) Bank balance (other than cash and cash equivalents)	81.04	49.0
	(iv) Other current Financial assets	11.12	8.5
0	c) Other current assets	196.55	129.2
(d) Assets classified as held for sale	144.29	56.6
	Sub-total - Current assets	2,430.92	1,606.5
	TOTAL ASSETS	5,366.80	4,759.8
E	EQUITY AND LIABILITIES		
1	Equity		
	(a) Equity share capital	55.38	55.3
		1,661.99	939.2
10	(b) Other Equity	1,001.99	939.
	Sub-total- Equity	1,717.37	994.6
21	Liabilities		
1.1	Non- Current liabilities		
	(a) Financial liabilities		
ľ	(i) Borrowings	421.73	519.6
	(ii) Lease Liabilities	409.91	424.8
		35.97	32
	(b) Provisions		
0	(c) Other non-current liabilities	472.04	483.1
	Sub-total- Non-current liabilities	1,339.65	1,459.0
	Current liabilities		
	(a) Financial liabilities		
ľ	(i) Borrowings	803.94	880.1
	(ii) Trade payables		
	a. Total outstanding dues of Micro enterprises and		
	Small enterprises	16.13	34.9
	b. Total outstanding dues of creditors other than		
	micro enterprises and small enterprises	349.04	489.4
	(iii) Lease Liabilities	70.57	69.
	(iv) Other financial liabilities	749.80	702.9
		90.83	71.0
	(b) Other current liabilities	E Contraction of the second se	
	(c) Provisions	59.33	43.0
	(d) Current tax liabilities (Net)	170.14	0.1
((e) Liabilities classified as held for sale	-	11
	Sub-total- Current liabilities	2,309.78	2,305.
	TOTAL EQUITY AND LIABILITIES	5,366.80	4,759.
		FOR WOCKHAI	
		thoras	way
		-	0
umba	ai	H F KHOR	6
	ai November 02, 2020		AKIWALA

Registered Office: D-4 MIDC, Chikalthana, Aurangabad - 431 006 Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051

UNAUDITED CASH FLOW STATEMENT FOR SIX MONTHS ENDED SEPTEMBER 30, 2020

PARTICULARS	6 MONTHS ENDED 30/09/2020	(Rs. in Crore) 6 MONTHS ENDED 30/09/2019
(Refer notes below)	Unaudited	Unaudited
Cash Baudean Wared in Constitute antibitian		
Cash flow from/(used in) Operating activities	(420.27)	
Loss before tax from Continuing Operations	and the second se	(205.58)
Profit before tax from Discontinued Operations	1,484.19	73.88
Adjustments for:	14 470 201	
Profit from Transfer of Business Undertaking	(1,470.32)	-
Impairment of property, plant and equipment	142.48	86.40
Depreciation and amortisation expense Allowance for credit loss	32.27	8.25
	02.21	3.48
Provision for doubtful advances Bad Debts		1.12
Loss on assets sold/write off of fixed assets (net)	0.25	0.16
	105.58	110.53
Finance costs Unrealised foreign fluctuation loss, net	22.44	19.81
interest income	(12:88)	(2.75)
Employee share based payments expenses	1.29	1.35
Liabilities no more payable	(6.87)	(1.38
Fair valuation impact on deposits	1.37	(1.39
Guaraniee fees income	(4.43)	(5.36
Guarance rees income	(4.40)	(0.50)
Operating (loss)/profit before working capital changes	(35.83)	88.50
Adjustments for changes in Working capital		
(Increase)/Decrease in Inventories	(21.76)	22.92
Increase in Trade receivables	(76.67)	(37.68)
(Increase)/Decrease in Loans and Advances and other assets	(50.11)	41.32
(Decrease)/Increase in Liabilities and provisions	(33.42)	27.89
Decrease in Trade payables	(157.11)]	(12.25)
Cash (used)/generated from operations	(374.90)	130.70
Income tax paid	(55.87)	(0.32
Net cash (outflow)/inflow from Operating activities	(430.77)	130.38
Cash flow from/(used in) Investing activities	(100.11)	
Purchase of Property, Plant and Equipment, Capital work- in progress and Intangible assets	(300.58)	(16.46)
Proceeds from sale of Property, Plant and Equipment	2.90	0.06
Consideration received from Transfer of Business Undertaking, net	1,534.50	•
Margin money under lien and Bank balances (other than cash and cash equivalents)	(31.69)	(1.86)
Interest received	9.81	4.29
Net cash inflow/(outflow) Investing activities	1,214.94	(13.97)
Cash flow from/(used in) Financing activities		Sales Street
Proceeds from Issuance of Equity share capital	0.01	0.03
Repayment of long-term borrowings	(23.30)	(139.41)
Short-term borrowings (net)	(47.87)	16.10
Loans from Related parties	-	20.00
Repayment of loans taken from Related parties	(58.40)	-
Repayment of Lease liabilities (refer note 3 below)	(36.44)	(35.52)
Finance costs paid	(36.07)	(73.00)
Equity Dividend paid (including dividend distribution tax, if any)		0.34
Net cash outflow from Financing activities	(202.07)	(211.46)
Net Increase/(Decrease) in Cash and Cash equivalents	582.10	(95.05)
Cash and cash equivalents as at the beginning of the period	108.46	177.07
Cash and cash equivalents as at the end of the period	890.56	82.02

Reconciliation of cash and cash equivalents as per the cash flow statement

	As at 30/09/2020	As at 30/09/2019
Cash and cash equivalents as per above comprise of the following		1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1
Cash	0.06	-
Balance with banks:		
- in current account	21.00	72.00
Deposits with maturity of less than 3 months	669.50	10.02
Balance as per the Statement of cash flows	690.56	82.02

Notes:

1. The above statement of cash flows has been prepared under the indirect method as set out in Ind AS 7 'Statement of Cash Flows':

Income taxes paid are treated as arising from operating activities and are not bifurcated between investing and financing activities.

3. Repayment of lease liabilities consists of:

Payment of interest Rs. 22.64 crore (Previous period - Rs. 23.85 crore) Payment of Principal Rs. 13.80 crore (Previous period - Rs. 11.67 crore)

The cash flows of the Discontinued Operations for the period are presented below:	6 MONTHS	(Rs. In Crore) 6 MONTHS
Particulars	ENDED 30/09/2020	ENDED 30/09/2019
Net cash inflow from Operating activities	5.82	83.10
Net cash inflow/joutflow) from Investing activities	1,584.50	(0.43
Net cash inflow from Financing activities	-	-

5. Figures in Gracket indicate cash outlow.

FOR WOCKHARDT LIMITED

thoración aly

H F KHORAKIWALA CHAIRMAN DIN: 00045608

Mumbai Date : November 02, 2020

Registered Office: D-4 MIDC, Chikalthana, Aurangabad - 431 008 Global Headquarters: Wockhardt Towers, Bandra Kurta Complex, Bandra (East), Mumbai 400 051 CIN: L24230MH1999PLC120720 Tel: 91 22 2653 4444; Fax: 91 22 2652 3905; e-mail id: investorrelations@wockhardt.com, Website: www.wockhardt.com

	STATEMENT OF CONSOLIDATED UNAUDITED RE					20	pt per share da
	PARTICULARS	3 MONTHS ENDED 30/09/2020	3 MONTHS ENDED 30/06/2020	3 MONTHS ENDED 30/09/2019	6 MONTHS ENDED 30/09/2020	6 MONTHS ENDED 30/09/2019	YEAR ENDED 31/03/2020
	(Refer Notes Below)	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Income from Continuing Operations (a) Revenue from Continuing operations	714.05	598.27	682.89	1,312.32	1,408.47	2,843.9
	(b) Other income	16.24	7.95	(0.20)	24.19	7.88	2,043.5
-	Total income	730.29	606.22	682.69	1,336.51	1,416.35	2,882.8
	Expenses from Continuing Operations						
	a) Cost of materials consumed b) Purchase of stock-in-trade	217.32 127.36	116.99 159.07	136.24	334.31	294.77	621.7
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(51.69)	(57.77)	132.74 20.08	286.43 (109.46)	264.55 46.86	507.7 74.0
1	d) Employee benefits expense	197.37	202.49	186.56	399.86	389.47	743.3
	e) Finance costs	60.90	73.70	64.66	134.60	135.57	275.7
	f) Depreciation and amortisation expense (g) Exchange fluctuation loss / (gain), net	57.15 10.59	55.96 8.66	52.50 (4.44)	113.11 19.25	107.05 11.23	224.1
	(h) Other expenses	196.4	240.88	198.86	437.28	389.14	(21.2
_	total expenses	815.40	799.98	787.20	1,515.38	1,638.64	3,224.6
1	Loss before exceptional items and tax from Continuing Operations (1-2)	(85.11)	(193.76)	(104.51)	(278.87)	(222.29)	(342.0
	Discontinued Operations Profit before exceptional items and tax from Discontinued Operations	-	13.87	33.96	13.87	73.88	145.3
E	Exceptional items- credit/(charge) a) Continuing Operations- (Refer note 4)		(142.40)		(1.12.40)		
	b) Discontinued Operations- (Refer note 3)		(142.48) 1,470.32		(142.48) 1,470.32		
1	Total Exceptional Items		1,327.84		1,327.84		
_	loss after exceptional items before tax from Continuing Operations (3 ± 5a)	(85.11)	(336.24)	(104.51)	(421.35)	(222.29)	(342.)
1	Tax expense of continuing operations : Current tax - credit	(12.17)	(66.12)	(13.02)	(78.29)	(20.10)	(48.
	Tax pertaining to earlier years			-	-	-	3.
,	Deferred tax - (credit)/ charge Net Profit / (Loss) from Continuing Operations (6 ± 7)	(76.23) 3.29	(44.54) (225.58)	24.84 (116.33)	(120.77) (222.29)	(23.01) (179.18)	(159.)
5	Profit after exceptional items before tax from Discontinued Operations (4 ± 5b)		1,484.19	33.96	1,484.19	73.88	145.3
-	ax expense of discontinued operations:						
+	Cuttent tax - charge		311.49	11.87	311.49	25.82	50.
	Deferred tax - charge		187.37		187.37	-	-
and the second second	Profit from Discontinued Operations (9 ± 10) Profit / (Loss) for the period (8 ±11)	3.29	985.33 759.75	22.09	985.33 763.04	48.06	94.5
_	Attributable to :	3.23	/39./3	(94.24)	/03.04	(131.12)	(43.3
E	quity shareholders of the Company	3.55	760.06	(82.17)	763.61	(127.15)	(69.3
the second second	Non - Controlling Interest	(0.26)	(0.31)	(12.07)	(0.57)	(3.97)	25.8
0	Other Comprehensive Income from Continuing Operations a) Items that will not be reclassified to Profit or Loss - (charge) / credit (consisting of re-measurement of net defined benefit (liability) / asset)	0.51	1.12	(13.84)	1.63	(8.18)	(2.9
	b) Income tax relating to items that will not be reclassified to Profit or Loss - charge) / credit	(0.25)	(0.54)	2.46	(0.79)	1.59	(3.4
	c) Items that will be reclassified to Profit or Loss - (charge) / credit (Consisting of	(4.77)	14.07	(1.70)	0.20	(0.37)	107.7
E	exchange differences on translating the financial statements of foreign	(4.77)	14.07	(1.76)	9.30	(0.37)	107.3
-	d) Other Comprehensive Income from continuing operations (net of tax) (a ± b ±	(4.51)	14.65	(13.14)	10.14	(6.96)	100.9
	Other Comprehensive Income from Discontinued Operations						
	a) Items that will not be reclassified to Profit or Loss - (charge) / credit (consisting of re-measurement of net defined benefit (liability) / asset)		(0.04)	(0.05)	(0.04)	(0.09)	(0.1
	b) Income tax relating to items that will not be reclassified to Profit or Loss - charge) / credit	-	0.01	0.02	0.01	0.03	0.0
Ľ	c) Other Comprehensive Income from discontinued operations (net of tax) (a ± b)	-	(0.03)	(0.03)	(0.03)	(0.06)	(0.1
T	otal Comprehensive Income (12 ± 13 (d) ± 14 (c))	(1.22)	774.37	(107.41)	773.15	(138.14)	57.4
A	Attributable to :						
	quity shareholders of the Company	(0.89)	771.85	(93.52)	770.96	(133.26)	1.5
_	Ion Controlling Interest aid-up equity share capital (face value of Rs. 5/- each)	(0.33)	2.52	(13.89)	2.19	(4.88)	55.9
_	Other Equity excluding Revaluation Reserves as per Balance Sheet		1	55.51	30.30	12.21	2,616.3
E	amings per equity share for continuing operations (face value of Rs. 5/- each)	-					
	*not annualised)						
	a) Basic (Rs.)	0.32*	(20.34)*	(9.42)*	(20.02)*	(15.83)*	(14.7
	b) Diluted (Rs.)	0.32*	(20.34)*	(9.42)*	(20.02)*	(15.83)*	(14.7
	amings per equity share for discontinued operations (face value of Rs. 5/- each) *not annualised)						
	a) Basic (Rs.)		88.98*	2.00*	88.98*	4.34*	8.
1	b) Diluted (Rs.)	- 1	88.64*	1.99*	88.61*	4.32*	8.
	arnings per equity share for continuing and discontinued operations (face value						
0	f Rs. 5/- each) (*not annualised)						
0	f Rs. 5/- each) (*not annualised) a) Basic (Rs.) b) Diluted (Rs.)	0.32* 0.32*	68.64* 68.37*	(7.42)* (7.42)*	68.96* 68.67*	(11.49)* (11.49)*	(6.2

Notes To Consolidated Results:-

- The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on November 2, 2020. The results have been subjected to limited review by the Statutory 1) Auditors of the Company.
- The Consolidated Results relate to Wockhardt Limited ('the Company' or 'the Holding Company') and its Subsidiaries (together constitute 'the Group') and are prepared by applying Ind AS 110 -2) "Consolidated Financial Statements".
- 3) The Board of Directors, in their meeting held on June 09, 2020, concluded the Business transfer agreement ("BTA") entered into between the Company and Dr. Reddy's Laboratories Limited ("Purchaser") dated February 12, 2020 read with amendments made time to time for the transfer of the business comprising 62 products and line extensions along with related assets and liabilities, contracts, permits, intellectual properties, employees, marketing, sales and distribution of the same in the Domestic Branded Division in India, Nepal, Bhutan, Sri Lanka and Maldives, and the manufacturing facility at Baddi, Himachal Pradesh, where some of the products which are being transferred were manufactured (together the "Business Undertaking"), to the Purchaser. The consideration for the above said transfer of Business Undertaking for Rs. 1,850 crore was structured as per following :

a)an amount equal to Rs. 1,550 crore (including a deposit of Rs. 67 crore in escrow account towards adjustments for, inter alia, Net working capital, employee liabilities and certain other contractual and statutory liabilities) to be paid on the Closing Date under the BTA. The said amount has been paid by the Purchaser to the Company during the half year ended September 30, 2020 including release of Rs. 63 crore out of the original escrow account of Rs.57 crore and,

b) balance amount equal to Rs. 300 crore out of total consideration of Rs. 1,850 crores has been held back ("Holdback Amount"), by the Purchaser on the Closing Date (i.e, 9th June 2020) for assessment of the impact of the COVID-19 pandemic on the Business Undertaking and shall be released as equal to 2 (two) times the amount by which the revenue exceeds Rs. 480 crore from sales of the products forming part of the said Business Undertaking by the Purchaser during the 12 months post-closing date.

The profit from aforesaid Transfer of Business Undertaking (excluding the Roldback Amount of Rs. 300 crore) amounting to Rs. 1,470.32 crore has been shown as 'Exceptional Items - discontinued operations'.

During the half year, the Company reassessed the commercial prospects of the Nutrition Business and decided not to pursue it in near future and therefore, the Nutrition Business assets were classified as 1 assets held for disposal and an impairment loss of Rs. 142.48 crore has been recognised under the head 'Exceptional items - continuing operations'.

Key Financials on Standalone basis: 5)

			A second second second second			(Rs. In Crore)
PARTICULARS	3 MONTHS ENDED 30/09/2020	3 MONTHS ENDED 30/06/2020	3 MONTHS ENDED 30/09/2019	6 MONTHS ENDED 30/09/2020	6 MONTHS ENDED 30/09/2019	YEAR ENDED 31/03/2020
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Total Income (continuing operation)	309.92	187.32	307.00	497.24	530.29	933.08
Loss before tax from continuing operation	(87.29)	(332.98)	(32.48)	(420.27)	(205.58)	(483.68)
Loss after tax from continuing operation	(57.38)	(218.94)	(22.02)	(276.32)	(130.92)	(325.68)
Profit before tax from discontinued operation	-	1,484.19	33.96	1,484.19	73.88	145.36
Profit after tax from discontinued operation	-	985.33	22.09	985.33	48.06	94.56

Note: The unaudited standalone results have been filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Regulations) Regulations, 2015 and are available on the Stock Exchanges websites (www.nseindia.com and www.bseindia.com) and also on the Company's website www.wockhardt.com.

The Group continues to monitor the impact of COVID-19 on it businesses across the globe, its customers, vendors, employees, productions, supply chain and logistics etc. The Group has exercised due care 6) in significant accounting judgements and estimates in relation to recoverability of receivables, investments and inventories based on the information available to date, both internal and external, while preparing the Group's financial results for the current period.

During the quarter ended September 30, 2020, the Company has allotted 21,950 Equity shares of face value of Rs. 5/- each pursuant to exercise of employee stock options. 7)

- The Group is exclusively into Pharmaceutical business Segment. 8)
- For List of Subsidiaries as on September 30, 2020 please refer Annexure. 9)
- Previous period / year figures have been recast / re-grouped to conform to the current period's presentation.

FOR WOCKHARDT LIMITED

(De In Croro)

Morarlin a

H F KHORAKIWALA CHAIRMAN DIN: 00045608

Mumbai Date : November 2, 2020



Registered Office: D-4 MIDC, Chikalthana, Aurangabad - 431 006 Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051

STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES

	PARTICULARS	As at Period Ended 30/09/2020	As at Year End 31/03/2020
		Unaudited	Audited
AS	SSETS		
1 N	on- Current assets		
(a)) Property, Plant and Equipment	1,648.70	1,856.6
) Right of use assets	600.40	622.2
1000	Capital work-in-progress	689.65	836.4
) Goodwill on consolidation	905.47	875.1
) Other Intangible assets	160.83	148.2
) Intangible assets under development	749.06	748.0
) Financial assets	1.5.00	
(B		0.45	0.4
	(i) Non-current investments	45.36	46.0
	(ii) Other non- current Financial assets		
	n) Non-current tax assets (Net)	120.52	118.9
(i)) Deferred tax assets (Net)	361.62	429.4
(1)	Other non-current assets	66.61	67.4
	Sub-total - Non-current assets	5,348.67	5,749.0
	Sub-total - Non-turient assets	3,510.07	3,74510
	urrent assets		689.8
) Inventories	847.14	689.8
	b) Financial assets		
	(i) Trade receivables	948.63	1,242.6
	(ii) Cash and cash equivalents	840.69	219.3
	(iii) Bank balances other than cash and cash equivalents	81.17	49.1
+	(iv) Other current Financial assets	11.15	8.8
	Other current assets	247.57	163.3
		144.29	56.6
10	d) Asset classified as held for sale	144.23	50.0
	Sub-total - Current assets	3,120.64	2,429.8
	TOTAL ASSETS	8,469.31	8,178.9
E	QUITY AND LIABILITIES		
1			
	quity a) Equity share capital	55.38	55.3
		3,398.96	2,616.3
	b) Other Equity	and the second se	the local data in the local data in the local data where the local data is not the local data where the local data is not the local data in the local data is not the local data in the local data is not the local data in the loca
	quity attributable to the share holders of the Company	3,454.34	2,671.6
1(c	c) Non - Controlling Interest	387.98	385.7
		0.040.00	A AF
-	Sub-total- Equity	3,842.32	3,057.4
	iabilities	3,842.32	3,057.4
2 4		3,842.32	3,057.4
2 LI 1: N	iabilities	3,842.32	3,057.4
2 LI 1: N	iabilities Ion- Current liabilities a) Financial liabilities	3,842.32	
2 LI 1: N	iabilities Ion- <u>Current liabilities</u> a) Financial liabilities i) Borrowings		1,240.9
2 LI <u>I: N</u> (a	iabilities ion- Current liabilities a) Financial liabilities i) Borrowings ii) Lease Liabilities	1,022.04 298.47	3,057.4 1,240.9 306.5 45.6
2 LL <u>1: N</u> (a	iabilities ion- <u>Current liabilities</u> a) Financial liabilities i) Borrowings ii) Lease Liabilities b) Provisions	1,022.04 298.47 41.15	1,240.9 306.5 45.6
2 LL <u>1: N</u> (a	abilities ion- Current liabilities a) Financial liabilities i) Borrowings ii) Lease Liabilities b) Provisions c) Deferred tax liabilities (Net)	1,022.04 298.47 41.15 30.36	1,240.9 306.5 45.6 31.2
2 LL <u>1: N</u> (a	iabilities ion- <u>Current liabilities</u> a) Financial liabilities i) Borrowings ii) Lease Liabilities b) Provisions	1,022.04 298.47 41.15 30.36	1,240.9 306.5 45.6 31.2
2 Li 1: N (a (b (c II. C	iabilities ion- Current liabilities a) Financial liabilities i) Borrowings ii) Lease Liabilities b) Provisions c) Deferred tax liabilities (Net) Sub-total- Non-current liabilities Current liabilities	1,022.04 298.47 41.15 30.36	1,240.9 306.5 45.6 31.2
2 Li <u>1: N</u> (a (b (c II. C	labilities lon- <u>Current liabilities</u> a) Financial liabilities i) Borrowings ii) Lease Liabilities b) Provisions c) Deferred tax liabilities (Net) Sub-total- Non-current liabilities	1,022.04 298.47 41.15 30.36 1,392.02	1,240.9 306.5 45.6 31.2 1,624.2
2 Li 1: N (a (b (c II. C	iabilities ion- Current liabilities a) Financial liabilities i) Borrowings ii) Lease Liabilities b) Provisions c) Deferred tax liabilities (Net) Sub-total- Non-current liabilities Current liabilities	1,022.04 298.47 41.15 30.36	1,240.9 306.5 45.6 31.2 1,624.2
2 Li 1: N (a (b (c II. C	iabilities lon- Current liabilities a) Financial liabilities i) Borrowings ii) Lease Liabilities b) Provisions c) Deferred tax liabilities (Net) Sub-total- Non-current liabilities a) Financial liabilities (i) Borrowings	1,022.04 298.47 41.15 30.36 1,392.02	1,240.9
2 Li 1: N (a (b (c II. C	iabilities ion- Current liabilities a) Financial liabilities i) Borrowings ii) Lease Liabilities b) Provisions c) Deferred tax liabilities (Net) Sub-total- Non-current liabilities a) Financial liabilities (i) Borrowings (ii) Trade payables	1,022.04 298.47 41.15 30.36 1,392.02	1,240.9 306.5 45.6 31.2 1,624.2
2 Li 1: N (a (b (c II. C	iabilities ion- Current liabilities a) Financial liabilities i) Borrowings ii) Lease Liabilities b) Provisions c) Deferred tax liabilities (Net) Sub-total- Non-current liabilities a) Financial liabilities (i) Borrowings (ii) Trade payables a. Total outstanding dues of Micro enterprises and	1,022.04 298.47 41.15 30.36 1,392.02 803.94	1,240.9 306.5 45.6 31.2 1,624.2 903.8
2 Li 1: N (a (b (c II. C	labilities lon- Current liabilities a) Financial liabilities i) Borrowings ii) Lease Liabilities b) Provisions c) Deferred tax liabilities (Net) Sub-total- Non-current liabilities a) Financial liabilities (i) Borrowings (ii) Trade payables a. Total outstanding dues of Micro enterprises and Small enterprises	1,022.04 298.47 41.15 30.36 1,392.02	1,240.9 306.5 45.6 31.2 1,624.2 903.8
2 Li 1: N (a (b (c II. C	labilities lon- Current liabilities a) Financial liabilities i) Borrowings ii) Lease Liabilities b) Provisions c) Deferred tax liabilities (Net) Sub-total- Non-current liabilities c) Deferred tax liabilities (Net) Sub-total- Non-current liabilities i) Financial liabilities (i) Borrowings (ii) Trade payables a. Total outstanding dues of Micro enterprises and Small enterprises b. Total outstanding dues of creditors other than	1,022.04 298.47 41.15 30.36 1,392.02 803.94 16.13	1,240.9 306.5 45.6 31.2 1,624.2 903.8 34.8
2 Li 1: N (a (b (c II. C	labilities lon- Current liabilities a) Financial liabilities i) Borrowings ii) Lease Liabilities b) Provisions c) Deferred tax liabilities (Net) Sub-total- Non-current liabilities a) Financial liabilities (i) Borrowings (ii) Trade payables a. Total outstanding dues of Micro enterprises and Small enterprises b. Total outstanding dues of creditors other than micro enterprises and small enterprises	1,022.04 298.47 41.15 30.36 1,392.02 803.94 16.13 511.13	1,240.9 306.5 45.6 31.2 1,624.2 903.8 34.8 860.3
2 Li 1: N (a (b (c II. C	labilities lon- Current liabilities a) Financial liabilities i) Borrowings ii) Lease Liabilities b) Provisions c) Deferred tax liabilities (Net) Sub-total- Non-current liabilities c) Deferred tax liabilities (Net) Sub-total- Non-current liabilities i) Financial liabilities (i) Borrowings (ii) Trade payables a. Total outstanding dues of Micro enterprises and Small enterprises b. Total outstanding dues of creditors other than	1,022.04 298.47 41.15 30.36 1,392.02 803.94 16.13 511.13 63.16	1,240.9 306.5 45.6 31.2 1,624.2 903.8 34.8 860.3 62.5
2 Li 1: N (a (b (c II. C	labilities lon- Current liabilities a) Financial liabilities i) Borrowings ii) Lease Liabilities b) Provisions c) Deferred tax liabilities (Net) Sub-total- Non-current liabilities a) Financial liabilities (i) Borrowings (ii) Trade payables a. Total outstanding dues of Micro enterprises and Small enterprises b. Total outstanding dues of creditors other than micro enterprises and small enterprises	1,022.04 298.47 41.15 30.36 1,392.02 803.94 16.13 511.13	1,240.9 306.5 45.6 31.2 1,624.2 903.8 34.8
2 U (a (b (c II. C) (a	labilities ton- Current liabilities a) Financial liabilities i) Borrowings ii) Lease Liabilities b) Provisions c) Deferred tax liabilities (Net) Sub-total- Non-current liabilities (i) Enancial liabilities (i) Borrowings (ii) Trade payables a. Total outstanding dues of Micro enterprises and Small enterprises b. Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Lease Liabilities (iv) Other financial liabilities	1,022.04 298.47 41.15 30.36 1,392.02 803.94 16.13 511.13 63.16	1,240.9 306.5 45.6 31.2 1,624.2 903.8 34.8 860.3 62.5
2 Li t: N (a (b (c li. C) (a (t	abilities ton- Current liabilities a) Financial liabilities i) Borrowings ii) Lease Liabilities b) Provisions c) Deferred tax liabilities (Net) Sub-total- Non-current liabilities c) Deferred tax liabilities (i) Borrowings (ii) Trade payables a. Total outstanding dues of Micro enterprises and Small enterprises b. Total outstanding dues of creditors other than micro enterprises and small enterprises (ii) Lease Liabilities (iv) Other financial liabilities (b) Other current liabilities	1,022.04 298.47 41.15 30.36 1,392.02 803.94 16.13 511.13 63.16 1,397.79 162.78	1,240.9 306.5 45.6 31.2 1,624.2 903.8 34.8 860.3 62.5 1,387.9 117.9
2 U t: N (a (b (c U (a (b) (c) (c) (c) (c) (c) (c) (c) (c) (c) (c	labilities lon- Current liabilities a) Financial liabilities i) Borrowings ii) Lease Liabilities b) Provisions c) Deferred tax liabilities (Net) Sub-total- Non-current liabilities c) Deferred tax liabilities (i) Borrowings (ii) Trade payables a. Total outstanding dues of Micro enterprises and Small enterprises b. Total outstanding dues of creditors other than micro enterprises and small enterprises (ii) Lease Liabilities (ii) Lease Liabilities (iv) Other financial liabilities (b) Other current liabilities (c) Provisions	1,022.04 298.47 41.15 30.36 1,392.02 803.94 16.13 511.13 63.16 1,397.79 162.78 102.55	1,240.9 306.5 45.6 31.2 1,624.2 903.8 34.8 860.3 62.5 1,387.9 117.9 117.2
2 Li (a (b (c li. (a (t (c) (c) (c) (c) (c) (c) (c) (c) (c) (c)	labilities lon- Current liabilities a) Financial liabilities ii) Borrowings ii) Lease Liabilities b) Provisions c) Deferred tax liabilities (Net) Sub-total- Non-current liabilities a) Financial liabilities (ii) Borrowings (ii) Trade payables a. Total outstanding dues of Micro enterprises and Small enterprises b. Total outstanding dues of creditors other than micro enterprises and small enterprises (ii) Lease Liabilities (ii) Lease Liabilities (iv) Other financial liabilities (b) Other current liabilities (c) Provisions d) Current tax liabilities (Net)	1,022.04 298.47 41.15 30.36 1,392.02 803.94 16.13 511.13 63.16 1,397.79 162.78	1,240.9 306.5 45.6 31.2 1,624.2 903.8 34.8 860.3 62.5 1,387.9 117.9 117.2 0.9
2 Li (a (b (c li. C) (a (t) (c) (t) (c)	labilities lon- Current liabilities a) Financial liabilities i) Borrowings ii) Lease Liabilities b) Provisions c) Deferred tax liabilities (Net) Sub-total- Non-current liabilities c) Deferred tax liabilities (i) Borrowings (ii) Trade payables a. Total outstanding dues of Micro enterprises and Small enterprises b. Total outstanding dues of creditors other than micro enterprises and small enterprises (ii) Lease Liabilities (ii) Lease Liabilities (iv) Other financial liabilities (b) Other current liabilities (c) Provisions	1,022.04 298.47 41.15 30.36 1,392.02 803.94 16.13 511.13 63.16 1,397.79 162.78 102.55 177.49	1,240.9 306.5 45.6 31.2 1,624.2 903.8 34.8 860.3 62.5 1,387.9 117.9 117.2
2 Li (a (b (c li. C) (a (t) (c) (t) (c)	labilities lon- Current liabilities a) Financial liabilities ii) Borrowings ii) Lease Liabilities b) Provisions c) Deferred tax liabilities (Net) Sub-total- Non-current liabilities c) Deferred tax liabilities (ii) Ease Liabilities (ii) Trade payables a. Total outstanding dues of Micro enterprises and Small enterprises b. Total outstanding dues of creditors other than micro enterprises and small enterprises (ii) Lease Liabilities (ii) Lease Liabilities (ii) Other current liabilities (ii) Other current liabilities (b) Other current liabilities (c) Provisions d) Current tax liabilities (Net) e) Liabilities classified as held for sale	1,022.04 298.47 41.15 30.36 1,392.02 803.94 16.13 511.13 63.16 1,397.79 162.78 102.55 177.49 	1,240.9 306.5 45.6 31.2 1,624.2 903.8 34.8 860.3 62.5 1,387.9 117.9 117.2 0.9 11.4

FOR WOCKHARDT LIMITED

the areas al

H F KHORAKIWALA CHAIRMAN DIN: 00045608

Mumbai

Date : November 2, 2020

Registered Office: D-4 MIDC, Chikalthana, Aurangabad - 431 006 Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051

CONSOLIDATED UNAUDITED CASH FLOW STATEMENT FOR SIX MONTHS ENDED SEPTEMBER 30, 2020

	6 MONTHS ENDED	(Rs in crore) 6 MONTHS ENDED	
PARTICULARS	6 MONTHS ENDED 30/09/2020	6 MONTHS ENDED 30/09/2019	
(Refer notes below)	Unaudited	Unaudited	
	Unouncu	COT INFORMATION OF	
CASH FLOWS FROM / (USED IN) OPERATING ACTIVITIES:			
Loss before tax from Continuing Operations	(421.35)	(222.29)	
Profit before tax from Discontinued Operations	1,484.19	73.88	
Adjustments for :			
Profit from Transfer of Business Undertaking	(1,470.32)		
Depreciation and amortization expense	113.13	108.32	
Allowance for credit loss	46.48	12.79	
Bad debts	0.09	1.12	
Loss on assets sold/write off of fixed assets (net)	8.81	1.40	
Finance costs	134.60	135.53	
Exchange loss	19.25	19.81	
Interest income	(16.47)	(2.69)	
Employee share based payments	1.29	1.35	
Liabilities no more payable	(6.87)	(1.39)	
Fair valuation impact on deposits	1.27	1.13	
Impairment of property, plant and equipment	142.48		
	36.58	128.96	
Operating profit before Working Capital changes	50.58	128.90	
Adjustments for changes in Working capital	(154.94)	88.52	
(Increase)/Decrease in Inventories	247.39	142.14	
Decrease in trade receivables	(64.44)	52.31	
(Increase)/Decrease in Loans and Advances and other assets (Decrease)/Increase in Liabilities and provisions	(336.38)	11.21	
Adjustment for translation difference in working capital	5.33	(7.79	
Adjustment for translation difference in working capiton			
Cash (used in)/ generated from operations	(266.45)	415.35	
Income taxes paid	(58.02)	(1.25	
Net cash (used in)/ generated from Operating Activities (A)	(324.47)	414.10	
CASH FLOWS FROM / (USED IN) INVESTING ACTIVITIES:			
		100.00	
Purchase of Property, Plant and Equipment, Capital work-in progress and Intangible asse	ts (76.25)	(89.62)	
Proceeds from sale of property, plant and equipment	3.57	0.06	
Consideration received from Transfer of Business Undertaking, net	1,534.50	0.00	
Margin money under lien and Bank balances (other than cash and cash equivalents)	(31.69)	(2.02	
Margin money under lien and bank balances (other than cash and cash olymorens)	(01.00)	1	
	9.81	4.94	
Interest received	5.04	4.34	
Not each from / (used in) Investing Articities (B)	1,439.94	(86.64	
Net cash from / (used in) Investing Activities (B)	10004	100.00	
CASH FLOWS FROM / (USED IN) FINANCING ACTIVITIES			
Proceeds from Issuance of Equity share capital	0.01	0.03	
Repayment of long-term borrowings	(253.18)	(408.00	
Short-term borrowings (net)	(47.87)		
Loans from related parties		20.00	
Repayment of loans taken from related parties	(81.45)		
Repayment of Lease liabilities (refer note 3 below)	(32.08)	and the second se	
Finance costs paid	(75.87)		
Equity Dividend paid (including dividend distribution tax, if any)		0.34	
Net cash used in Financing Activities (C)	(490.44)	(527.23	
NET INCREASE/ (DECREASE) IN CASH AND CASH EQUIVALENTS (A+B+C)	625.03	(199.77	
CASH AND CASH EQUIVALENTS, at beginning of period	219.34	397.34	
Unrealised loss on foreign currency cash and cash equivalents	(4.87)	(1.04	
Exchange difference on translation of foreign cash and cash equivalents	1.19	-	
CASH AND CASH EQUIVALENTS, at end of period	240.50	196.53	
Components of cash and cash equivalents:			
Cash	0.09	0.00	
Balance with banks:			
	171.10	186.43	
- in current accounts	1/1.10		
- in current accounts - deposit with maturity of less than 3 months	669.50	10.02	

Notes:

Mumbai

Date : November 2, 2020

1. The above statement of cash flows has been prepared under the indirect method as set out in Ind AS 7 'Statement of Cash Flows'.

2. Income taxes paid are treated as arising from operating activities and are not bifurcated between investing and financing activities.

3. Repayment of lease liabilities consists of:

Payment of interest Rs. 16.54 crore (Previous period - Rs. 17.55 crore) Payment of Principal Rs. 15.54 crore (Previous period - Rs. 14.27 crore)

4. The cash flows of the Discontinued Operations for the period are presented below:

(Rs. in Crore)

Particulars		6 MONTHS ENDED 30/09/2019
Net cash inflow from Operating activities	5.82	83.10
Net cash inflow/(outflow) from Investing activities	1,534.50	(0.43
Net cash inflow from Financing activities	-	-

5. Figures in bracket indicate cash outflow.

FOR WOCKHARDT LIMITED

Thoracio -

H F KHORAKIWALA CHAIRMAN DIN: 00045608

Registered Office: D-4 MIDC, Chikalthana, Aurangabad - 431 006 Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051

Annexure to Note 9 of Consolidated Unaudited Results for the Quarter and Six Months ended September 30, 2020

List of Subsidiaries as on September 30, 2020

- 1 Wockhardt UK Holdings Limited
- 2 CP Pharmaceuticals Limited
- 3 CP Pharma (Schweiz) AG
- 4 Wallis Group Limited
- 5 The Wallis Laboratory Limited
- 6 Wockhardt Farmaceutica Do Brasil Ltda
- 7 Wallis Licensing Limited
- 8 Wockhardt Infrastructure Development Limited
- 9 Z & Z Services GmbH
- 10 Wockhardt Europe Limited
- 11 Wockhardt Nigeria Limited
- 12 Wockhardt USA LLC
- 13 Wockhardt UK Limited
- 14 Wockpharma Ireland Limited
- 15 Pinewood Laboratories Limited
- 16 Pinewood Healthcare Limited
- 17 Laboratoires Negma S.A.S.
- 18 Wockhardt France (Holdings) S.A.S.
- 19 Wockhardt Holding Corp.
- 20 Morton Grove Pharmaceuticals Inc.
- 21 MGP Inc.
- 22 Laboratoires Pharma 2000 S.A.S.
- 23 Niverpharma S.A.S.
- 24 Negma Beneulex S.A.
- 25 Phytex S.A.S.
- 26 Wockhardt Farmaceutica SA DE CV
- 27 Wockhardt Services SA DE CV


28 Wockhardt Bio AG


29 Wockhardt Bio (R) LLC

30 Wockhardt Bio Pty Limited

31 Wockhardt Bio Limited

32 Wockhardt Medicines Limited





14th Floor, Central Wing, Tower 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063, India Telephone: +91 (22) 6257 1000 Fax: +91 (22) 6257 1010

Limited Review Report on Unaudited Quarterly and Year to Date Standalone Financial Results of Wockhardt Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of Wockhardt Limited

- We have reviewed the accompanying Statement of unaudited standalone financial results of Wockhardt Limited ("the Company") for the quarter ended and year to date results for the period from 1 April 2020 to 30 September 2020 ("the Statement").
- 2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of

company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For BSR & Co. LLP

Chartered Accountants Firm's Registration No: 101248W/W-100022

Koosai Lehery Partner Membership No: 112399 ICAI UDIN: 20112399AAAACP5519

Mumbai 2 November 2020

B.S.R.& Co.ls pattiership finiti with Registration No. BAS1223] converted into B.S.R.& Co. LLP (a Limited Liability, Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013. Registered Office: 14th Floot, Central Wing, Tower 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063



14th Floor, Central Wing, Tower 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063, India Telephone: +91 (22) 6257 1000 Fax: +91 (22) 6257 1010

Limited Review Report on Unaudited Quarterly and Year to Date Consolidated Financial Results of Wockhardt Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of Wockhardt Limited

- 1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Wockhardt Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended and year to date results for the period from 1 April 2020 to 30 September 2020 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
- 2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review


Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the financial information of the following entities:

Name of the Entity	Relationship
 Wockhardt UK Holdings Limited (including its following subsidiaries and its step-down subsidiaries) a) Wallis Group Limited b) The Wallis Laboratory Limited c) Wallis Licensing Limited d) Wockhardt Farmaceutica Do Brasil Ltda 	Wholly Owned Subsidiary

B S R & Co la partnership firm with Registration No. 6A51223 converted into B S R & Co. LLP (a Limited Liability, Partnership with LLP Registration No. AA6-5161) with effect from October 14, 2013 Registered Office: 14th Floor, Central Wing, Tower 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063



BSR&Co.LLP

Wockhardt Limited 2 November 2020 Page 2 of 3

Limited Review Report on Unaudited Quarterly and Year to Date Consolidated Financial Results of Wockhardt Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Continued)

Wockhardt Limited

	Name of the Entity	Relationship
2) Woo	ckhardt Infrastructure Development Limited	Wholly Owned Subsidiary
who	ckhardt Europe Limited (including its following olly owned subsidiary) Wockhardt Nigeria Limited	Wholly Owned Subsidiary
4) Woo	ckhardt Medicines Limited	Wholly Owned Subsidiary
(inc subs a) b) c) d) e) f) g) h) i) j) k) l) m) n)	ckhardt Bio AG Juding its following subsidiaries and its step-down sidiaries) CP Pharmaceuticals Limited CP Pharma (Schweiz) AG Z & Z Services GmbH Wockhardt UK Limited Wockpharma Ireland Limited Pinewood Laboratories Limited Pinewood Healthcare Limited Laboratories Negma S.A.S. Wockhardt France (Holdings) S.A.S. Wockhardt Holding Corp. Wockhardt USA LLC Morton Grove Pharmaceuticals Inc. MGP Inc. Laboratories Pharma 2000 S.A.S. Niverpharma S.A.S. Negma Beneulex S.A. Phytex S.A.S. Wockhardt Farmaceutica SA DE CV Wockhardt Bio (R) LLC Wockhardt Bio Pty Limited	Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

BSR&Co.LLP

Wockhardt Limited 2 November 2020 Page 3 of 3

Limited Review Report on Unaudited Quarterly and Year to Date Consolidated Financial Results of Wockhardt Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Continued)

Wockhardt Limited

- We did not review the interim financial information of four subsidiaries included in the 6. Statement, whose interim financial information reflect total assets (before consolidation adjustments) of Rs 6,019.55 crores as at 30 September 2020 and total revenues (before consolidation adjustments) of Rs 656.48 crores and Rs 1,350.10 crores, total net profit after tax (before consolidation adjustments) of Rs 170.75 crores and Rs 337.27 crores and total comprehensive income (before consolidation adjustments) of Rs 170.25 crores and Rs 335.84 crores, for the guarter ended 30 September 2020 and for the period from 1 April 2020 to 30 September 2020, respectively, and cash outflows (net) (before consolidation adjustments) of Rs 41.64 crores for the period from 01 April 2020 to 30 September 2020, as considered in the unaudited consolidated financial results. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of the above matter.
- 7. The Statement includes the interim financial information of twenty two subsidiaries which have not been reviewed, whose interim financial information reflect total assets (before consolidation adjustments) of Rs 392.58 crores as at 30 September 2020 and total revenue

(before consolidation adjustments) of Rs 27.98 crores and Rs 53.10 crores, total net profit after tax (before consolidation adjustments) of Rs 3.75 crores and Rs 3.38 crores and total comprehensive loss (before consolidation adjustments) of Rs 3.75 crores and Rs 3.38 crores for the quarter ended 30 September 2020 and for the period from 1 April 2020 to 30 September 2020, respectively, and cash inflows (net) (before consolidation adjustments) of Rs 68.51 crores for the period from 01 April 2020 to 30 September 2020, as considered in the Statement. According to the information and explanations given to us by the management, these interim financial information are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

For BSR & Co. LLP

Chartered Accountants Firm's Registration No: 101248W/W-100022

Koosai Lehery Partner Membership No: 112399 ICAI UDIN: 20112399AAAACQ7104

Mumbai 2 November 2020